Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Tsuge, Masataka ^a,b   Fujimoto, Yoshifumi ^a,c   Hiraga, Nobuhiko ^a,b   Zhang, Yizhou ^a,b   Ohnishi, Mayu ^a,b   Kohno, Tomohiko ^a,b   Abe, Hiromi ^a,b   Miki, Daiki ^a,b,d   Imamura, Michio ^a,b   Takahashi, Shoichi ^a,b   Ochi, Hidenori ^a,b,d   Hayes, C Nelson ^a,b   Miya, Fuyuki ^d   Tsunoda, Tatsuhiko ^d   Chayama, Kazuaki ^a,b,d  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Division of Dermatology   (Japan)

^d INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COMPLEMENTARY DNA; CXCL9 CHEMOKINE; INTERFERON;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CHIMERA; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFICACY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC ASSOCIATION; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE GENE; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; MOUSE; MX1 GENE; NONHUMAN; SIGNAL TRANSDUCTION; STAT1 GENE; UPREGULATION; ANIMAL; DRUG RESISTANCE; IMMUNE EVASION; IMMUNOLOGY; INNATE IMMUNITY; LIVER; PATHOLOGY; VIROLOGY;

HEPATITIS C VIRUS; MUS;

ANIMALS; CHIMERA; DRUG RESISTANCE; HEPATITIS C; HEPATOCYTES; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INTERFERONS; LIVER; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 80052010610     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023856     Document Type: Article

References (62)

1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, et al. (1989) Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321: 1494-1500.
2. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, et al. (1999) Analysis of a successful immune response against hepatitis C virus. Immunity 10: 439-449.
3. Lee SH, Kim YK, Kim CS, Seol SK, Kim J, et al. (2005) E2 of hepatitis C virus inhibits apoptosis. J Immunol 175: 8226-8235.
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
5. Hoofnagle JH, Ghany MG, Kleiner DE, Doo E, Heller T, et al. (2003) Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 38: 66-74.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
7. Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, et al. (2004) HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 40: 831-836.
8. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, et al. (2007) Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 50: 361-368.
9. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, et al. (2005) Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48: 372-380.
10. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470-477.
11. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81.
12. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
13. Kitamura S, Tsuge M, Hatakeyama T, Abe H, Imamura M, et al. (2010) Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antivir Ther 15: 1087-1097.
14. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, et al. (2008) Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads. Dig Dis Sci.
15. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
16. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, et al. (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6: 981-988.
17. Seth RB, Sun L, Ea CK, Chen ZJ, (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122: 669-682.
18. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, et al. (2005) VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 19: 727-740.
19. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ, (2005) Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 102: 17717-17722.
20. Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen X, et al. (2007) Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 81: 8953-8966.
21. Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, et al. (2007) Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A 104: 1661-1666.
22. Moriishi K, Okabayashi T, Nakai K, Moriya K, Koike K, et al. (2003) Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol 77: 10237-10249.
23. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, et al. (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4: 1065-1067.
24. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, et al. (2001) Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61: 4365-4370.
25. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, et al. (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78 (Pt 7): 1527-1531.
26. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, et al. (2008) PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118: 683-694.
27. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, et al. (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7: 927-933.
28. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, et al. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165: 901-912.
29. Hiraga N, Imamura M, Tsuge M, Noguchi C, Takahashi S, et al. (2007) Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett 581: 1983-1987.
30. Kimura T, Imamura M, Hiraga N, Hatakeyama T, Miki D, et al. (2008) Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. J Gen Virol 89: 2108-2113.
31. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, et al. (2005) Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42: 1046-1054.
32. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
33. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
34. Joyce MA, Walters KA, Lamb SE, Yeh MM, Zhu LF, et al. (2009) HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog 5: e1000291.
35. Walters KA, Joyce MA, Thompson JC, Smith MW, Yeh MM, et al. (2006) Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. PLoS Pathog 2: e59.
36. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, et al. (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46: 1548-1563.
37. Lanford RE, Guerra B, Lee H, Chavez D, Brasky KM, et al. (2006) Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 43: 961-972.
38. Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, et al. (2006) Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 44: 1122-1138.
39. Caillot F, Derambure C, Bioulac-Sage P, Francois A, Scotte M, et al. (2009) Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. World J Gastroenterol 15: 300-309.
40. Caillot F, Hiron M, Goria O, Gueudin M, Francois A, et al. (2009) Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. Am J Pathol 175: 46-53.
41. Toh PP, Li JJ, Yip GW, Lo SL, Guo CH, et al. (2010) Modulation of metallothionein isoforms is associated with collagen deposition in proliferating keloid fibroblasts in vitro. Exp Dermatol 19: 987-993.
42. Brassard DL, Grace MJ, Bordens RW, (2002) Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71: 565-581.
43. Clemens MJ, Elia A, (1997) The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17: 503-524.
44. Dong B, Silverman RH, (1995) 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 270: 4133-4137.
45. Platanias LC, Fish EN, (1999) Signaling pathways activated by interferons. Exp Hematol 27: 1583-1592.
46. Samuel CE, (2001) Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809 table of contents.
47. Staeheli P, Pitossi F, Pavlovic J, (1993) Mx proteins: GTPases with antiviral activity. Trends Cell Biol 3: 268-272.
48. Bishop KN, Holmes RK, Sheehy AM, Malim MH, (2004) APOBEC-mediated editing of viral RNA. Science 305: 645.
49. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, et al. (2006) Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43: 1364-1374.
50. Lecossier D, Bouchonnet F, Clavel F, Hance AJ, (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300: 1112.
51. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
52. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21-31.
53. Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, et al. (2007) Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol 88: 432-440.
54. Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, et al. (2005) G to A hypermutation of hepatitis B virus. Hepatology 41: 626-633.
55. Rosler C, Kock J, Kann M, Malim MH, Blum HE, et al. (2005) APOBEC-mediated interference with hepadnavirus production. Hepatology 42: 301-309.
56. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32: 2421-2429.
57. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
58. Komohara Y, Yano H, Shichijo S, Shimotohno K, Itoh K, et al. (2006) High expression of APOBEC3G in patients infected with hepatitis C virus. J Mol Histol 37: 327-332.
59. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, et al. (2009) Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 137: 309-319, 319 e301-303.
60. Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, et al. (2005) Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129: 2064-2075.
61. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039.
62. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499-509.